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Abstract: The ergogenic effects of caffeine on performance are well documented. These effects 
are more evident in endurance and short-duration, sustained-effort events than in interactive or 
stop-go sports. Experimentally-induced placebo effects of caffeine on sports performance have 
also been observed in a number of recent studies. In the present paper it is argued that, given 
the nature of the sports in which caffeine effects are observed, the well documented hypoalgesic 
effects of caffeine, and the fact that pain is highly placebo-responsive, a reduction in perceived 
pain might be the common factor in both the biologic and placebo ergogenic effects of caffeine 
on sports performance. This idea is supported by evidence from medicine that suggests placebo 
effects are often associated with mechanisms similar or identical to those of the substance the 
subject believes they have ingested. Research findings from both biomedicine and sports medicine 
that attest to the interaction of biologic and psychologic factors in caffeine and pain responses 
are briefly reviewed. In conclusion, it is recommended that researchers investigate the pain 
hypothesis. Furthermore, researchers should consider psychosocial factors that might modulate 
the pain response as variables of interest in future caffeine and performance research.
Keywords: caffeine hypoalgesia, nocebo effects, research methods
Introduction
The ergogenic effects of caffeine on sports performance are well documented.1 
Although these effects have been observed in a wide variety of sports, they are 
generally more evident in endurance and sustained high-intensity closed skill sports 
than in interactive and stop-go sports.2 The ergogenic effects of caffeine can be 
obtained at doses at or below the daily intake of normal populations,3 and below 
levels representing health risks. Caffeine is not currently proscribed by the World 
Anti-Doping Agency. Several mechanisms for the ergogenic effects of caffeine 
have been proposed, including enhanced fat oxidation, sympathetic nervous system 
enhancement, reduction in central fatigue, attenuation of neuromuscular conduction 
block, and potentiation of muscular force output for given input.4 These mechanisms 
are not consistently supported by research evidence, eg, Graham et al concluded that 
there is very little evidence to support the fat oxidation theory,1 whilst Tarnopolsky 
suggested there is no evidence for caffeine-induced changes in peripheral nerve 
conduction or neuromuscular transmission.4 The lack of consistent support for any 
one physiologic mechanism, and the fact that an increasing number of studies in 
sport and elsewhere have demonstrated significant and substantial placebo effects 
of caffeine,5–10 suggests that psychologic factors might play a significant role in 
caffeine effects.
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Perhaps the obvious psychologic factor to consider is 
pain. The proposal that caffeine ingestion reduces pain 
in performance is supported by both experimental find-
ings and the anecdotal reports of athletes.5,11 Furthermore, 
caffeine-induced pain reduction could explain, in part, both 
biologic and placebo effects of caffeine on performance. 
Such a pain hypothesis is supported by a number of factors. 
Firstly, caffeine has well documented hypoalgesic or pain-
reducing properties,12 secondly, pain is a limiting factor on 
performance,13 thirdly, pain is highly placebo responsive,14 
and lastly, the sports in which ergogenic effects of caffeine 
have been observed tend to be those in which athletes expe-
rience substantial levels of sustained pain without the relief 
of regular disruption of activity associated with stop-go or 
interactive sports. Given that pain is also highly socially 
modifiable and context-dependent,14 a pain hypothesis might 
explain the interindividual variability in caffeine response 
observed in sport research.15 The present paper aims to 
examine the potential influence of psychosocial factors in the 
ergogenic effect of caffeine in the context of caffeine-induced 
pain reduction. The article will review selected findings dem-
onstrating placebo effects of caffeine on sports performance, 
hypoalgesic effects of caffeine on sports performance, and 
placebo effects on pain in experimental and clinical medicine. 
It will also briefly discuss implications for research.
Placebo effects of caffeine  
on sports performance
Placebo effects of caffeine on sports performance have been 
reported in three recent experimental studies. Beedie et al 
examined the possibility of a dose-response relationship 
to placebos presented as “zero”, “low”, and “high” dose 
caffeine among seven well-trained competitive cyclists.5 
Measures were power, heart rate, oxygen uptake, and blood 
lactate. Following habituation and baseline trials, subjects 
were informed that, over three experimental trials, they 
would receive a placebo, or 4.5 mg/kg or 9.0 mg/kg caffeine 
double-blind and randomly assigned. However, a biologically 
inert placebo was administered in all experimental condi-
tions. Postexperimental baseline trials were also conducted. 
A dose-response relationship was evident in experimental 
trials, with subjects producing 1.4% (range, −4.6%–1.9%) 
less power than baseline when they believed they had ingested 
a placebo, 1.3% (−1.4%–4.1%) more power than at baseline 
when they believed they had ingested 4.5 mg/kg caffeine, and 
3.1% (0.4%–6.7%) more power than at baseline when they 
believed they had ingested 9.0 mg/kg caffeine. Of further 
interest was the fact that no substantial differences in any 
measured physiologic variables between baseline and experi-
mental conditions were observed. Follow-up interviews with 
each subject indicated that five subjects believed that they had 
experienced a placebo effect, proposing mechanisms such as 
pain reduction, fatigue resistance, changes in strategy, and 
reduced arousal.
Pollo et al investigated the effects of a caffeine placebo 
on quadriceps muscle performance and perceived fatigue.6 
Forty-four recreationally active males were divided into 
four groups, ie, two control and two placebo (n = 11 each). 
In the first experiment, a placebo was deceptively adminis-
tered, with the suggestion that it was a high dose of caffeine. 
This resulted in a significant increase in mean muscle work 
(11.8%–16.1%, P , 0.01) but no perceived decrease in 
muscle fatigue (P . 0.05). In the second experiment, placebo 
caffeine administration was accompanied by a conditioning 
procedure whereby the weight to be lifted was surreptitiously 
reduced. The load was then restored to the original weight and 
placebo caffeine administered again. Compared with the first 
experiment, the placebo effect was larger, with a significant 
increase in muscle work (22.1%–23.5%, P , 0.01) and a 
decrease in perceived muscle fatigue (−7.8–10.1, P , 0.01). 
The authors suggested that their findings indicated a central 
mechanism of topdown modulation of the global performance 
of muscles by placebo and underscore the role of learning in 
the placebo response.
Foad et al used the balanced placebo design with 14 
well-trained competitive cyclists in a study examining 
the effects of caffeine and placebo on 40 km laboratory 
cycling performance.7 Subjects performed two 40 km time 
trials in each of four experimental conditions (informed 
 caffeine/received caffeine, informed no-treatment/received 
 caffeine, informed caffeine/received placebo, and informed 
 no- treatment/received no treatment). Measures were power, 
oxygen uptake, blood lactate, and heart rate. The authors 
reported a very likely beneficial main effect on mean power 
of receiving caffeine (3.5% ± 2.0%), and a possibly beneficial 
main effect of being informed of caffeine (0.7% ± 1.4%). 
A substantial interaction between belief and pharmacology 
(2.6% ± 3.3%) indicated that caffeine exerted a greater effect 
on performance when subjects were informed that they had 
not ingested it, while belief exerted a greater influence on 
performance in the absence of caffeine. A possibly harmful 
negative placebo (nocebo) effect relative to baseline was 
present when subjects were correctly informed that they 
had ingested no caffeine (−1.9% ± 2.2%). No substantial 
changes relative to baseline were observed in mean heart rate, 
although clear and substantial increases in blood lactate were 
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evident following the receipt of caffeine. The within-subject 
CV for power in deceptive conditions at 2.8% was 1.7 times 
larger than the CV when subjects were truthfully informed 
that they were receiving caffeine, indicating the possibility of 
some disparity between internal sensations and instructions 
amongst some subjects. The authors suggested that their data 
supported the ergogenic efficacy of caffeine, but noted that in 
the absence of caffeine, the negative effect on performance 
of negative expectation was somewhat more substantial than 
the positive effect of positive expectation (a finding that could 
inflate effect sizes in placebo-controlled studies).
Evidence for placebo effects associated with caffeine has 
also been provided elsewhere.8–10 It is evident from these find-
ings that whilst caffeine ingestion often exerts an influence on 
behavior, so too can beliefs about caffeine, and about whether 
or not caffeine has been ingested. These findings beg several 
questions as to the likely ergogenic mechanisms of caffeine 
and suggest a significant psychologic contribution.
Hypoalgesic effects of caffeine  
in sports performance
As suggested above, perhaps the most likely psychologic 
contribution would be pain reduction. There is a large body 
of evidence attesting to the hypoalgesic properties of  caffeine 
in both medicine16 and physical activity.5,12,17,18  Consistent 
with this are data demonstrating that subjects’ ratings of 
perceived exertion are lower when given  caffeine.19 Pain is 
a highly complex biopsychologic phenomenon, and even a 
brief overview of theories and potential mechanisms is well 
beyond the scope of this paper. It is reasonable to suggest that 
whilst pain is certainly not a necessary condition of sports 
performance, athletes in endurance and sustained short-
duration sports routinely experience pain in competition. 
Many will experience pain with little respite for a substantial 
part, if not for the entirety, of their event (as stated above, it 
is in such sports that caffeine’s ergogenic efficacy has been 
most widely demonstrated, lending further weight to the pain 
hypothesis). Gliottoni et al state that there is an expanding 
body of evidence that acute exercise is a natural stimulus 
that might transiently, safely, and reliably produce muscle 
pain,12 whilst Cook et al suggest that not only are descriptors 
used to describe pain during exercise similar to those that 
have been used to characterize clinical pain conditions,20 
but that pain ratings during exercise as measured by the 
short form of the McGill Pain Questionnaire are nearly one 
standard deviation above the mean scores associated with 
other laboratory methods of inducing pain.21 Research has 
suggested that  ingestion of caffeine significantly reduces the 
pain response  during performance.12,17,18,22,23 O’Connor et al 
reported that  caffeine ingestion has a dose-response effect 
on reducing leg muscle pain during exercise.22 Motl et al 
reported that leg muscle pain ratings were  significantly 
and moderately reduced after a high dose (10 mg/kg body 
weight) of  caffeine.18 Maridakis et al reported that caffeine 
produced a large and statistically significant hypoalgesia 
effect during maximal quadriceps contraction.23 Gliottoni and 
Motl reported that caffeine administration resulted in a large 
reduction in leg muscle pain intensity ratings.17  Gliottoni et al 
reported that caffeine ingestion is associated with a moderate 
hypoalgesic effect during high-intensity cycling.12 Theo-
retically, any intervention that reduces perceived exertion or 
pain should also increase the perceived headroom for effort, 
and therefore has the potential to enhance performance. 
A hypoalgesic effect driven by  caffeine could be direct, ie, the 
action of caffeine attenuates the perception of pain. Indirectly, 
caffeine actions could influence other biologic processes that 
attenuate the pain response. The effect could also result from 
both direct and indirect processes simultaneously. Whichever 
way, and significantly for the present discussion, the large 
body of research in medicine and psychology demonstrat-
ing substantial placebo effects on pain could shed some 
light on the placebo effects related to caffeine and sports 
performance.
Psychosocial modulation of pain
Pain is highly susceptible to social and psychologic 
modulation,14 and perhaps because of this, over the last 
few years, pain has become one of the most fruitful areas 
of research into mind/body interaction. In short, evidence 
from such research demonstrates that expectation of pain 
relief can modify the subsequent effectiveness of admin-
istered substances, be they active analgesics, such as 
morphine, or inactive placebos. These effects can be both 
hypoalgesic and hyperalgesic. Several complex designs 
have been used to elucidate this phenomenon, ranging 
from covert manipulation of experimental pain stimuli, to 
direct comparison of the effects of the hidden/deceptive 
administration of biologically active treatments with the 
overt administration of biologically inactive substances. 
Studies using such designs are informative in demonstrating 
the degree to which pain can be modified by psychosocial 
processes, such as conditioning and  expectation. On that 
basis, they are of interest to those investigating or using 
interventions in which pain reduction might be a factor in 
their efficacy. Some illustrative examples of such studies 
are briefly described below.
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Montgomery and Kirsch exposed subjects to  experimental 
pain at baseline, and in subsequent trials surreptitiously 
reduced the pain stimulus whilst a placebo analgesic cream 
was administered (the latter process designed to lead subjects 
to believe that the cream had reduced the pain).24 Subjects were 
then split into two groups, the first was correctly informed 
about the deception, and the second was not informed. On 
re-exposure to the pain at baseline level, subjects who had 
been correctly informed of the deception experienced no pain 
relief when the placebo analgesia cream was applied, whilst 
those in the second group reported substantially lower pain. 
The authors also assessed subjects’ expectation of analgesia, 
and reported that this accounted for 49% of the observed 
effects. The authors concluded that an analgesic response 
can be conditioned, but that the conditioned response might 
be either reversed or suppressed by correct information or 
negative expectation respectively.
Levine et al administered active painkillers covertly and 
placebo painkillers openly to two groups of subjects follow-
ing dental surgery.25,26 They reported that the overt injection 
of a saline placebo described as morphine was as effective 
as a covert injection of morphine. Similarly, Benedetti et al 
compared the open administration of five different painkillers 
with the hidden and automated administration of the same 
drugs.27–29 The authors reported that in hidden administration 
conditions the time taken for postoperative pain to diminish 
by 50% was greatly increased for all drugs compared with 
open administration. These findings suggest that anticipation 
of analgesia is a factor in perceived analgesia.
Pollo et al treated postoperative patients with a painkiller 
on request for three consecutive days, as well as with a 
saline placebo (patients were given the intravenous saline 
as a background infusion in addition to the routine analgesic 
treatment).30 Subjects were divided into three groups, the 
first being told nothing about the saline, the second that they 
had a 50:50 chance of receiving the painkiller or a placebo, 
and the third that the saline solution was a potent painkiller 
(these three conditions forming, respectively, natural his-
tory, double-blind, and deceptive administration groups). 
The authors reported that, compared with the natural his-
tory group, a 20% decrease in requests for analgesia was 
observed in the double-blind group, and a 34% decrease 
in requests was observed in the deceptive administration 
group. The authors concluded that instructions that induce 
a certain expectation of analgesia induce greater placebo 
analgesia than those that induce uncertain expectation, a 
finding subsequently supported in a meta-analysis of 14 
similar studies.31
In an interesting twist on their open-versus-hidden 
 administration design above, Benedetti et al used open-
 versus-hidden interruption of morphine treatment in post-
operative patients.28,29 The authors reported that patients 
who were aware that their treatment had been discontinued 
were more likely to request further morphine than those 
who were unaware that their treatment had been interrupted. 
 Similarly, Benedetti et al demonstrated pain increases associ-
ated with the administration of a placebo expected to increase 
pain in both clinical32 and experimental patients.33 The authors 
concluded that, in the same way that positive expectations of 
pain relief might induce or enhance actual pain relief, negative 
expectations might have the opposite effect.
Evidence for biologic mechanisms 
of placebo and nocebo effects  
on pain
Whilst early research into the psychosocial modulation of 
pain tended to focus on demonstrating the effect and specu-
lating as to mechanisms, recent research has gone beyond 
this to investigating mechanisms in real time using technol-
ogy such as positron emission tomography and magnetic 
resonance imaging. A classic experimental model is the 
administration of an agent known to antagonize the pathway 
that an administered placebo analgesic purports to mimic. 
For example, naloxone antagonizes the action of opiates such 
as morphine. Therefore, naloxone would also be expected 
to antagonize placebo analgesia if the same mechanisms as 
for morphine were responsible. In the first study of its kind, 
Levine et al demonstrated that naloxone did in fact disrupt 
placebo analgesia, concluding, logically, that the endogenous 
opioids are involved in the placebo response.34 These findings 
were replicated several times in both experimental and clini-
cal settings. At the University of Turin, Benedetti et al further 
demonstrated that as well as the opioids, cholecystokinin, a 
neurotransmitter with an antiopioid action, plays a role in both 
placebo analgesia35 and nocebo hyperalgesia.32 Subsequent 
research has demonstrated, for example, placebo-induced 
activation of brain areas involved in the pain response,36 
placebo-induced deactivation of brain areas involved in 
pain processing,37 and correlations between the magnitude 
of placebo analgesia and dopamine activity.38
In a study of the placebo analgesia mechanism related to 
sports performance, Benedetti et al investigated the placebo 
analgesic effects of morphine on a pain endurance test.39 
Subjects had a tourniquet wrapped around their forearm and 
were required to squeeze a hand spring exerciser repeatedly 
until they could no longer continue. During precompetition 
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training, two “teams”, A and B, received no pharmacologic 
substance whilst teams C and D were trained with morphine. 
During competition, team A received no treatment while 
teams B and C were given placebo morphine one hour 
before competition. Team D also received what they believed 
was morphine, but they actually received naloxone (which 
would be expected to antagonize the opioid pathways). As 
hypothesized, the largest placebo effect on pain tolerance was 
observed in team C who received both the morphine precon-
ditioning in the “training” trials and also believed they had 
ingested morphine in the competition trials. In team D, who 
had received morphine in preconditioning trials, naloxone 
negated the morphine preconditioning effects. These find-
ings suggest conditioned activation of endogenous opioids 
after placebo administration, although a correlation between 
morphine and placebo suggests the possible contribution of 
nonopioid mechanisms. It is noteworthy that the placebo 
analgesic responses were obtained after only two morphine 
administrations separated by as much as a week. These long 
time intervals suggest that pharmacologic conditioning pro-
cedures have long-lasting effects (with implications for the 
use of proscribed drugs in training and competition).
Collectively, the findings above and many others suggest 
not only that placebo effects have biologic mechanisms, but 
that these mechanisms may be similar or identical to those 
of the drug the placebo mimics. Given this, and given the 
reduced ratings of perceived exertion/pain observed in both 
caffeine and placebo caffeine research, it is reasonable to 
speculate that pain reduction might be one mechanism by 
which both the biologic and placebo effects of caffeine on 
sports performance operate.
Implications
It is proposed above that pain might be a factor in the 
observed ergogenic effect of both caffeine and placebo caf-
feine on sports performance. This proposal was supported by 
a brief review of research that has demonstrated the placebo 
effects of caffeine on sports performance, the hypoalgesic 
effects of caffeine in exercise, and the psychosocial modula-
tion of pain responses. It is suggested that if pain reduction is 
a key factor in the ergogenic effect of caffeine, the findings 
of the latter body of research will be instrumental in elucidat-
ing mechanisms and explaining interindividual variability 
to response to caffeine. Specifically, these findings suggest 
that: an analgesic response can be conditioned and that the 
conditioned response might be either reversed or suppressed 
by correct information or negative expectation, respec-
tively; that expectation of analgesia is a factor in perceived 
 analgesia; that instructions that induce a certain expectation 
of analgesia induce greater analgesia than those that induce 
an uncertain expectation; and that negative expectations of 
analgesia associated with an analgesic intervention might 
offset some of the effectiveness of that intervention. If pain 
is indeed a factor in the ergogenic effect of caffeine, all of 
these findings are of interest to researchers investigating the 
phenomenon.
Beyond these findings, evidence from over 50 years of 
scientific research indicates that when a person receives any of 
a number of biomedical interventions, ranging from tablet to 
surgery, the brain might play a role in modulating the effective-
ness of that intervention.14,40–42 Whilst this fact is recognized 
by sports scientists, and is accounted for in our use of the 
placebo-controlled experimental design, such psychologic fac-
tors are rarely considered legitimate variables in experimental 
research. This is despite the growing experimental evidence 
for placebo effects on sports performance. Whilst this litera-
ture is reviewed elsewhere,43 it suffices to state that placebo 
effects on sports performance resulting from the belief that an 
ergogenic substance had been ingested have been reported in 
12 well-controlled studies.5–7,39,43–50 Most of these effects were 
in the range of 1%–5%. In three studies, nocebo (or negative 
placebo) effects were observed as the result of subjects either 
being given negative information about an intervention,44 hav-
ing previous negative experience with caffeine,5 or for reasons 
that were not entirely clear.12 Many of the positive effects were 
similar in magnitude to the effects of the substance that the 
placebo mimicked. In the few studies in which the biologically 
active substance was administered alongside the placebo, as 
is the case in the traditional placebo-controlled study, results 
were arguably not as easily interpretable as those in which 
placebos only were administered. This suggests that the interac-
tion of belief and biology in real time, or that order effects in 
which subjects were able to detect the presence or otherwise 
of the active substance, might have created tension between 
information (eg, “Today you have been given a placebo”) and 
perception (eg, “I’m sure this feels like I have been given 
caffeine”). This finding in itself warrants further investiga-
tion. Whilst knowledge that placebos might be powerful in 
the absence of the biologically active substance they mimic, 
such an application is rare in the real world which scientific 
research aims to inform.
Modifying research designs to 
understand caffeine effects better
Burke, in reviewing the caffeine and performance literature, 
argued strongly for more ecologically valid investigations 
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of the phenomenon.2 It is fair to argue that, in order to 
 understand any intervention fully, it is necessary to determine 
how it operates in the real world, outside of the laboratory. 
However, there are many aspects of the ergogenic effect of 
caffeine that can be examined in the laboratory, one of which 
is the contribution or otherwise of psychologic factors. The 
degree to which the brain is capable of modulating the bio-
logic effect of an intervention, be that modulation trivial, as 
is likely the case with a strong poison, or substantial, as has 
been suggested is the case with several complementary medi-
cine treatments, is still little explored in sports performance. 
Biomedical research is increasingly utilizing sophisticated 
and elegant designs to investigate this area, and in doing so, 
is providing a firm biologic basis for what were previously 
perceived as purely psychologic phenomena. The differences 
between the laboratory and the field and between research 
and competition are critical factors. Arguably as important, 
however, are differences between the subjects’ certainty of 
having received an intervention or of not having done so, or 
between their lack of faith in an intervention or extreme con-
fidence in the same intervention. Burke also highlighted the 
interindividual variability in response to caffeine ingestion 
in performance research.2 Much of this variability is likely 
the result of factors such as habituation, diet, training status, 
and available physiologic resources. The research described 
above suggests that, if pain reduction is indeed a mechanism 
of the ergogenic effects of caffeine, several psychosocial fac-
tors might also modulate the ergogenic effects of caffeine. It 
has been suggested that some athletes are nonresponsive to 
caffeine. It is, however, possible that if caffeine responses 
are context-dependent, an athlete who would not respond to 
caffeine in one context, for example, with no explicit expecta-
tion of effect, might respond in another context when given 
an explicit expectation or when exposed to a conditioning 
stimulus with false-positive performance outcome feedback. 
These factors are largely related to the subject’s expectations, 
or conditioned responses, to the caffeine intervention, and 
these themselves are dependent on either previous experience 
or currently available information. Therefore, to understand 
better the effects of caffeine on performance, these psycho-
social factors should be treated as variables of interest in 
caffeine research. Previous experiences of caffeine could 
be assessed, and in doing so, several aspects of the caffeine 
experience, including whether the previous intervention had 
a positive or negative effect on performance, or whether 
it was associated with any side effects, such as nausea or 
insomnia, could be factored in. It is also useful to evaluate the 
subjects’ expectations of caffeine. As was demonstrated by 
Beedie et al,5 expectations of a negative effect can result in a 
 substantial nocebo effect on performance, even in the absence 
of caffeine. In this respect it is also useful to evaluate whether 
a subject believes they were given caffeine or placebo in 
any one trial. Several recent studies have demonstrated that 
subjects who believed themselves to be in placebo control 
or no-treatment conditions performed below baseline, sug-
gesting a potentially powerful nocebo effect. Such an effect 
is perhaps associated with the hope/anticipation of a positive 
intervention being replaced by the disappointment/anxiety 
of no intervention. It is important to distinguish between 
controlling for current use of, or habituation to, caffeine and 
for previous use. Whilst the physiologic effects of caffeine 
might be extinct after a few days, conditioned responses, 
expectations, or both, might persist for several years or even 
indefinitely.
The suggestion that caffeine’s mechanisms might relate 
in part to psychologic factors is intuitively appealing, espe-
cially when considering the multiple feedback loops between 
brain and body during performance. However, to date, little 
research in sport has examined, or even considered, such 
biologic and psychologic interactions in this context. This is 
not surprising, given the complex links between perception 
of effort and pain and the biologic reality at that exact point 
in time. However, if sports scientists are to understand fully 
the mechanisms of interventions, such questions must, at the 
very least, be asked, if not immediately or easily answered. 
A substantial body of biomedical research has demonstrated 
that brain and body interact in response to the administration 
of a substance about which the subject has some expectation, 
be that expectation positive or negative. This is of course 
the case when an athlete uses caffeine, ie, the athlete has 
some expectation of an effect. Given the failure to defini-
tively support several longstanding theories of caffeine’s 
ergogenic effects described by Tarnopolsky above,4 and 
the increasing database of studies attesting to the potential 
psychologic contribution to the action of ergogenic aids in 
sports performance,42 it is perhaps timely to investigate the 
pain hypothesis, and consider psychosocial variables that 
might modulate the pain response, in future caffeine and 
performance research.
Summary
The ergogenic effects of caffeine have been observed in a 
number of sports. These effects are more evident in endurance 
sports or in short-duration, sustained-effort sports. In these 
sports, athletes would be expected to experience high levels of 
pain with little relief. There is, however, wide interindividual 
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 variability in the ergogenic response to caffeine. Placebo 
effects of caffeine have been observed on sports performance. 
Given that pain is a limiting factor on performance, that 
caffeine has well documented hypoalgesic effects, and that 
pain is highly placebo responsive, pain reduction might be a 
mechanism in both biologic and placebo caffeine responses 
in sport. This idea is supported by findings in medicine which 
suggest that biologic and placebo effects of analgesic drugs 
share common mechanisms. Researchers should further 
explore the pain hypothesis and, whilst doing so, consider 
psychosocial variables that might modulate the pain response 
in future caffeine and performance research.
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